Background Regeneron owned two patents relating to transgenic mice that produce hybrid antibodies containing human variable regions and mouse constant regions. More specifically, the claimed mice contain an in situ replacement at a murine chromosomal immunoglobulin...
Earlier this year we reported that the European Patent Office (EPO) has stated that the requirements for being an inventor can only be fulfilled by a natural person. The United States Patent and Trademark Office (USPTO) has now considered the parallel subject matter...
Background This case is a preliminary ruling from the Courts of Justice of the European Union (CJEU) following a referral from the German Federal Patent Court regarding Supplementary Protection Certificates. In particular, the referral relates to Article 3(a) of EU...
Genentech owns US Patents 7,846,441 and 7,892,549 which both relate to treating cancers characterised by overexpression of the ErbB2 receptor (which includes breast cancers). The claims of these two patents relate to treating a human patient with a combination of an...
“Crown Use”, by which the government can order the infringement of the patent under particular circumstances, is a provision of the UK Patents Act 1977 that is seldom used. However, in the case of IPCom vs Vodafone, this seldom used provision has been...
Recent Comments